SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Ferguson WS, Goorin AM. Current treatment of osteosarcoma. Cancer Invest 2001; 19: 292315.
  • 2
    Jaffe N. Recent advances in the chemotherapy of metastatic osteogenic sarcoma. Cancer 1972; 30: 162731.
  • 3
    Allegra CJ, Chabner BA, Drake JC, Lutz R, Rodbard D, Jolivet J. Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J Biol Chem 1985; 260: 97206.
  • 4
    Erttmann R, Bielack S, Landbeck G. Kinetics of 7-hydroxy-methotrexate after high-dose methotrexate therapy. Cancer Chemother Pharmacol 1985; 15: 1014.
  • 5
    Ekstrom PO, Andersen A, Saeter G, Giercksky KE, Slordal L. Continuous intratumoral microdialysis during high-dose methotrexate therapy in a patient with malignant fibrous histiocytoma of the femur: a case report. Cancer Chemother Pharmacol 1997; 39: 26772.
  • 6
    Jacobs SA, Stoller RG, Chabner BA, Johns DG. 7-Hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate. J Clin Invest 1976; 57: 5348.
  • 7
    Smeland E, Fuskevag OM, Nymann K, Svendesn JS, Olsen R, Lindal S, Bremnes RM, Aarbakke J. High-dose 7-hydromethotrexate: acute toxicity and lethality in a rat model. Cancer Chemother Pharmacol 1996; 37: 41522.
  • 8
    Lankelma J, van der Klein E, Ramaekers F. The role of 7-hydroxymethotrexate during methotrexate anti-cancer therapy. Cancer Lett 1980; 9: 13342.
  • 9
    Slordal L, Sager G, Aarbakke J. Pharmacokinetic interactions with methotrexate: is 7-hydroxy-methotrexate the culprit? Lancet 1988; 1: 5912.
  • 10
    Isacoff WH, Townsend CM, Eiber FR, Forster T, Morton DL, Block JB. High dose methotrexate therapy of solid tumors: observations relating to clinical toxicity. Med Pediatr Oncol 1976; 2: 31925.
  • 11
    Stoller RG, Hande KR, Jacobs SA, Rosenberg SA, Chabner BA. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med 1977; 297: 6304.
  • 12
    Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist 2006; 11: 694703.
  • 13
    Zelcer S, Kellick M, Wexler LH, Gorlick R, Meyers PA. The Memorial Sloan Kettering Cancer Center experience with outpatient administration of high dose methotrexate with leucovorin rescue. Pediatr Blood Cancer 2008; 50: 117680.
  • 14
    Bailey LB. Folate status assessment. J Nutr 1990; 120 (Suppl. 11): 150811.
  • 15
    Smeland S, Muller C, Alvegard TA, Wiklund T, Wiebe T, Bjork O, Stenwig AE, Willen H, Holmstrom T, Folleras G, Brosjo O, Kivioja A, Jonsson K, Monge O, Saeter G. Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer 2003; 39: 48894.
  • 16
    Bacci G, Ferrari S, Longhi A, Picci P, Mercuri M, Alvegard TA, Saeter G, Donati D, Manfrini M, Lari S, Briccoli A, Forni C. High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study. J Chemother 2002; 14: 198206.
  • 17
    Ferrari S, Smeland S, Mercuri M, Bertoni F, Longhi A, Ruggieri P, Alvegard TA, Picci P, Capanna R, Bernini G, Muller C, Tienghi A, Wiebe T, Comandone A, Bohling T, Del Prever AB, Brosjo O, Bacci G, Saeter G. Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol 2005; 23: 884552.
  • 18
    Del Prever AB, Smeland S, Tienghi A, Hall KS, Aglietta G, Bernini G, Bohling T, Berta M, Brosjo O, Ferrari S, Alvegaard TA. High-risk osteosarcoma (OS): preliminary results of the ISG-SSG II protocol. J Clin Oncol 2005; 23: 884552. No. 16S, Part I of II.
  • 19
    Smeland S, Bruland OS, Hjorth L, Brosjo O, Bjerkehagen B, Osterlundh G, Jakobson A, Hall KS, Monge OR, Bjork O, Alvegaard TA. Scandinavian experience in classical osteosarcoma Results of the SSG XIV protocol. Acta Orthop Suppl 2010; 80: 606.
  • 20
    Saeter G, Alvegard TA, Elomaa I, Stenwig AE, Holmstrom T, Solheim OP. Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: a Scandinavian Sarcoma Group study. J Clin Oncol 1991; 9: 176675.
  • 21
    Lawson GJ, Dixon PF, Aherne GW. Rapid and simple method for the measurement of methotrexate and 7-hydroxymethotrexate in serum by high-performance liquid chromatography. J Chromatogr 1981; 223: 22531.
  • 22
    Seidel H, Andersen AM, Nygaard R, Moe PJ, Jacobsen G, Slørdal L. Variability in methotrexate serum and cerebrospinal fluid pharmacokinetics in children with acute lymphocytic leukemia: relation to assay methodology and physiological variables. Leuk Res 2000; 24: 1939.
  • 23
    U.S. National Institutes of Health. National Cancer Institute CTEP CTCAE v3.0. 2011. Available at http://ctep.cancer.gov/reporting/ctc.html (last accessed June 2011).
  • 24
    Sterba J, Dusek L, Demlova R, Valik D. Pretreatment plasma folate modulates the pharmacodynamic effect of high-dose methotrexate in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma: ‘folate overrescue’ concept revisited. Clin Chem 2006; 52: 692700.
  • 25
    Valik D, Sterba J, Bajciova V, Demlova R. Severe encephalopathy induced by the first but not the second course of high-dose methotrexate mirrored by plasma homocysteine elevations and preceded by extreme differences in pretreatment plasma folate. Oncology 2005; 69: 26972.
  • 26
    Wang YM, Sutow WW, Romsdahl MM, Perez C. Age-related pharmacokinetics of high-dose methotrexate in patients with osteosarcoma. Cancer Treat Rep 1979; 63: 40510.
  • 27
    Rask C, Albertioni F, Bentzen SM, Schroeder H, Peterson C. Clinical and pharmacokinetic risk factors for high-dose methotrexate-induced toxicity in children with acute lymphoblastic leukemia–a logistic regression analysis. Acta Oncol 1998; 37: 27784.
  • 28
    Becker ML, Rosé CD, Cron RQ, Sherry DD, Bilker WB. Effectiveness and toxicity of methotrexate in juvenile idiopathic arthritis: comparison of 2 initial dosing regimens. J Rheumatol 2010; 37: 8705.
  • 29
    Robien K, Boynton A, Ulrich CM. Pharmacogenetics of folate-related drug targets in cancer treatment. Pharmacogenomics 2005; 6: 67389.
  • 30
    Rau T, Erney B, Gores R, Eschenhagen T, Beck J, Langer T. High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations. Clin Pharmacol Ther 2006; 80: 46876.
  • 31
    Hulot JS, Villard E, Maguy A, Morel V, Mir L, Tostivint I, William-Faltaos D, Fernandez C, Hatem S, Deray G, Komajda M, Leblond V, Lechat P. A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination. Pharmacogenet Genomics 2005; 15: 27785.
  • 32
    Baggott JE, Bridges SL, Jr, Morgan SL. Evidence for two phenotypes in the metabolism of methotrexate to 7-hydroxymethotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2005; 52: 3568.
  • 33
    Borsi JD, Sagen E, Romslo I, Moe PJ. Comparative study on the pharmacokinetics of 7-hydroxy-methotrexate after administration of methotrexate in the dose range of 0.5–33.6 g/m2 to children with acute lymphoblastic leukemia. Med Pediatr Oncol 1990; 18: 21724.
  • 34
    Crews KR, Liu T, Rodriguez-Galindo C, Tan M, Meyer WH, Panetta JC, Link MP, Daw NC. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma. Cancer 2004; 100: 172433.